Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Wolfram-like syndrome is a rare endocrine disease characterized by the triad of adult-onset diabetes mellitus, progressive hearing loss (usually presenting in the first decade of life and principally of low to moderate frequencies), and/or juvenile-onset optic atrophy. Psychiatric (i.e. anxiety, depression, hallucinations) and sleep disorders, the only neurologic abnormalities observed in this disease, have been reported in rare cases. Unlike Wolfram syndrome, patients with Wolfram-like syndrome do not report endocrine or cardiac findings.
Features include always present findings: Blind-spot enlargement, Hearing loss (hearing impairment), and Reduced visual acuity; and very common findings: Inner ear hearing loss (sensorineural hearing impairment) and Damage to the optic nerve (optic atrophy). 18 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Blind-spot enlargement, Damage to the optic nerve (optic atrophy), Optic disc pallor |
WFS1 function has not been fully characterized.
Wolfram-like syndrome is caused by mutations in the WFS1 gene on chromosome 4.
No genotype-phenotype correlations have been identified for classic WFS1-SD or nonclassic WFS1-SD.
Classic WFS1-SD should be suspected in individuals with any of the following clinical findings and family history. Major clinical findings :
Diabetes mellitus (onset age usually 16 years)
Optic atrophy (onset age usually 16 years)
Additional clinical findings may include one or more of the following:
No approved treatments are currently available for Wolfram-like syndrome. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with classic or nonclassic WFS1 spectrum disorder (WFS1-SD), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. See also Wolfram Syndrome Clinical Management Guidelines, page 5, for recommended baseline investigations.
See also Wolfram Syndrome Clinical Management Guidelines, pages 6-12, for surveillance recommendations. Classic WFS1 Spectrum Disorder To monitor existing manifestations, the response of an individual with classic WFS1-SD to supportive care, and the emergence of new manifestations, the evaluations in are recommended. Table 7. Recommended Surveillance for Individuals with Classic WFS1 Spectrum Disorder
No clinical trials have been registered for Wolfram-like syndrome.
113 publications have been identified in PubMed for Wolfram-like syndrome. Research spans Basic Science / Preclinical (80%), Review / Meta-Analysis (7%), and Case Report / Case Series (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 83 | 80% |
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Wolfram-like syndrome
Brain and nerves | 4 | Psychosis, Hallucinations, Depression |
Ears | 3 | Hearing loss (hearing impairment), Inner ear hearing loss (sensorineural hearing impairment), Progressive hearing impairment |
Hormones | 2 | Diabetes mellitus, Type II diabetes mellitus |
Muscles | 1 | Damage to the optic nerve (optic atrophy) |
Clinical Description – Classic WFS1 Spectrum Disorder Classic WFS1 spectrum disorder (WFS1-SD) is characterized by childhood-onset diabetes mellitus and progressive optic atrophy, with variable hearing impairment/ deafness, diabetes insipidus, neurologic abnormalities, and psychiatric abnormalities . Table 2. Select Features Associated with Classic WFS1 Spectrum Disorder
Feature | Common | Uncommon | Increases w/Age |
|---|---|---|---|
Diabetes mellitus, childhood onset | Diabetes mellitus, neonatal onset or adult onset | — | — |
Sensorineural hearing impairment | Cataracts | Cerebellar ataxia | Autonomic dysfunction |
Bowel dysfunction | Seizures | — | — |
Other endocrine findings | Central diabetes insipidus | — | — |
Hypogonadism | Hypothyroidism | Growth restriction | Based on data from , , , , , , , and 1. A comprehensive review of classic WFS1-SD, genotype-phenotype correlations, pathophysiology, and therapeutic strategies is available . |
Source: GeneReviews — "WFS1 Spectrum Disorder"
Source: GeneReviews — "WFS1 Spectrum Disorder"
High-tone sensorineural hearing impairment
Cerebellar ataxia
Psychiatric illness
Neurogenic bladder (overactive or underactive)
Other endocrine findings:
Central diabetes insipidus
Delayed puberty, particularly in males, associated with hypogonadism
Non-autoimmune hypothyroidism
Structural congenital heart defects
Source: GeneReviews — "WFS1 Spectrum Disorder"
Wolfram syndrome type 2 (WS2) (OMIM 604928) is an autosomal recessive disorder caused by biallelic pathogenic variants in CISD2. Like classic WFS1 spectrum disorder (WFS1-SD), WS2 presents as a continuum of clinical features; however, the full clinical spectrum of WS2 abnormalities has not yet been fully established because so few affected individuals have been described. To date, the following clinical features have been reported in individuals with WS2: • Families of Palestinian Arab origin have been described with juvenile-onset diabetes mellitus, optic atrophy, high-frequency sensorineural hearing impairment, urinary tract dilatation, impaired kidney function, hypogonadism, and severe gastrointestinal ulcer and bleeding ; abnormal facial features were described in one family . • Diabetes insipidus, psychiatric abnormalities, and variable degrees of optic atrophy have been reported in individuals from Italy and Morocco . Peptic ulcers, mucocutaneous bleeding, and defective platelet aggregation were also described in a subset of these individuals. Note: A novel CISD2 pathogenic variant (c.215AG; p.Asn72Ser) was identified in an individual with clinical findings suggestive of classic WFS1-SD who did not have WFS1 pathogenic variants . Other Genetic Causes of Features Seen in WFS1 Spectrum Disorder Hearing impairment. See Genetic Hearing Loss Overview. Monogenic diabetes syndromes. See . Table 3. Monogenic Diabetes Syndromes in the Differential Diagnosis of WFS1 Spectrum Disorder
Gene(s)/ Genetic Mechanism | Differential Disorder | MOI | Selected Features of Differential Disorder |
|---|---|---|---|
Endocrine abnormalities | Eye findings | Hearing loss | Neurologic abnormalities ALMS1 |
Alstrm syndrome | AR | Insulin resistance/ type 2 DM often presents in 2nd decade. Other endocrine abnormalities incl hypogonadotropic hypogonadism in boys, polycystic ovaries in girls, hypothyroidism. Obesity common, leading to non-alcoholic fatty liver disease. | Cone-rod dystrophy presents as progressive visual impairment, photophobia, nystagmus starting between birth age 15 mos; no light perception by age 20 yrs in many persons. |
Bardet-Biedl syndrome | AR | Insulin resistance/ type 2 DM in adolescence or adulthood; male hypogonadotropic hypogonadism. Obesity is common. | Cone-rod dystrophy; night blindness usually evident by age 7-8 yrs; mean age of legal blindness is 15.5 yrs. |
DMPK | Myotonic dystrophy type 1 (DM1) | AD | DM is common in mild classic DM1. |
Source: GeneReviews — "WFS1 Spectrum Disorder"
Genetic testing for WFS1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Wolfram-like syndrome has been reported in the published literature.
Recommended Evaluations Following Initial Diagnosis in Individuals with Classic or Nonclassic WFS1 Spectrum Disorder
System/Concern | Evaluation | Comment
| By diabetologist |
| Ophthalmologic eval | • Assess extraocular movement, best corrected visual acuity, visual evoked potentials.
Perform color vision testing, visual field testing, optical coherence tomography, fundus exam.
Optometry /or low-vision clinic | Assess for low-vision aids.
Sensorineural
hearing impairment | • Audiologic exam
Eval by speech-language therapist
| Incl:
Auditory brain stem responses to confirm pathology provide baseline
Evoked otoacoustic emissions to identify type of hearing impairment
Audiogram
Speech discrimination tests
Assessment for hearing aids; children w/profound infancy-onset deafness may require cochlear implant.
Neurologic
dysfunction | Neurologic exam incl brain MRI (if not performed previously) | Evaluate for:
Source: GeneReviews — "WFS1 Spectrum Disorder"
For a review of current and future therapeutic strategies, see . Classic WFS1-SD. An ongoing multicenter randomized double-blind controlled pivotal clinical trial is evaluating the use of sodium valproate to slow the progression of neurodegeneration (EudraCT Number 2017-001215-37). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "WFS1 Spectrum Disorder"
View trials for Wolfram-like syndrome
System/Concern |
|---|
Evaluation |
|---|
Frequency |
|---|
Diabetes mellitus | Glycemic control | Every 3 mos |
Complications of diabetes mellitus | Nephropathy | Annual screening starting at age 12 yrs Retinopathy |
Sensorineural hearing impairment | Audiogram incl assessment of speech discrimination | Every 1-2 yrs Neurologic |
Activities of daily living mobility | Physical medicine, OT/PT assessment of mobility, self-help skills | Per treating clinicians |
Dysphagia | For those w/o this concern previously: obtain history of swallowing/choking episodes refer to speech-language therapist as needed. | Annually For those known to have this concern |
Dysarthria | For those w/o this concern previously: obtain history of speech difficulties refer to speech-language therapist as needed. | Annually For those known to have this concern |
Source: GeneReviews — "WFS1 Spectrum Disorder"
Phenotype severity distribution: 3 always present features, 2 very common features, 6 common features.
7 |
7% |
Patient case studies | 7 | 7% |
New treatment approaches | 3 | 3% |
Disease patterns and progression | 2 | 2% |
Testing and diagnosis research | 1 | 1% |
Clinical study results | 1 | 1% |
Niu Y (2026). [PMID: 41530347](https://pubmed.ncbi.nlm.nih.gov/41530347/). *Cell Res*. [Basic Science / Preclinical]
Li M (2026). [PMID: 41015595](https://pubmed.ncbi.nlm.nih.gov/41015595/). *Cell Death Differ*. [Basic Science / Preclinical]
Mehrotra P (2026). [PMID: 42093864](https://pubmed.ncbi.nlm.nih.gov/42093864/). *JCEM Case Rep*. [Case Report / Case Series]
Jojima T (2026). [PMID: 42040055](https://pubmed.ncbi.nlm.nih.gov/42040055/). *Diabetol Int*. [Case Report / Case Series]
Fehrmann MLA (2025). [PMID: 39422244](https://pubmed.ncbi.nlm.nih.gov/39422244/). *Int J Audiol*. [Case Report / Case Series]
Yuan Q (2025). [PMID: 40065145](https://pubmed.ncbi.nlm.nih.gov/40065145/). *Cell Death Differ*. [Basic Science / Preclinical]
Liu C (2025). [PMID: 40641032](https://pubmed.ncbi.nlm.nih.gov/40641032/). *J Diabetes*. [Basic Science / Preclinical]
Hull S (2025). [PMID: 39552476](https://pubmed.ncbi.nlm.nih.gov/39552476/). *Ophthalmic Genet*. [Epidemiology / Natural History]
Cadena Sandoval M (2025). [PMID: 39757322](https://pubmed.ncbi.nlm.nih.gov/39757322/). *Nat Rev Endocrinol*. [Review / Meta-Analysis]
Miranda-Cervantes A (2025). [PMID: 39746949](https://pubmed.ncbi.nlm.nih.gov/39746949/). *Nat Commun*. [Basic Science / Preclinical]